Form 4: Apellis CPO Kelley Boucher Granted Future Equity Awards

Apellis Pharmaceuticals' Chief People Officer, Kelley Boucher, was granted 30,476 restricted stock units and options for 45,766 shares, effective September 2, 2025.

Summary

• Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted equity awards.
• On September 2, 2025, Boucher was granted 30,476 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs will vest 25% annually over four years from the grant date, contingent on her continued service as an officer or upon later termination of service.
• Additionally, on September 2, 2025, Boucher received a stock option award for 45,766 shares of common stock with an exercise price of $28.17 per share.
• The stock options have an expiration date of September 2, 2035.
• The stock options vest over a four-year period, with 25% vesting one year from the grant date and the remaining 75% vesting monthly thereafter, subject to continued service.
• Following these transactions, Boucher beneficially owns 97,658 shares of common stock directly and 45,766 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The filing reflects a positive sentiment as it details routine executive compensation designed to align management interests with shareholders and incentivize long-term performance and retention. It is a standard corporate governance practice.

Positives

• The equity grants align the Chief People Officer's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedules for both RSUs and stock options serve as a retention mechanism for a key executive.
• The grants are part of a pre-scheduled plan, indicating structured executive compensation.

Negatives

• The grants do not represent an immediate cash benefit to the executive, as they are subject to vesting conditions.
• The value of the stock options is dependent on the future stock price exceeding the exercise price of $28.17.

Risks

• Vesting of both restricted stock units and stock options is contingent upon Kelley Boucher's continued service, meaning unvested portions could be forfeited if her employment terminates.
• The ultimate value realized from the stock options is subject to the future market price of Apellis Pharmaceuticals' common stock, which can fluctuate.

Future Outlook

The grants of restricted stock units and stock options, with their multi-year vesting schedules, indicate an expectation of continued service from the Chief People Officer and a long-term incentive structure designed to align executive performance with shareholder value creation over the next four years.

Industry Context

Equity grants, including restricted stock units and stock options, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. They are widely used to attract, retain, and motivate key talent by linking executive wealth creation to the company's stock performance and long-term strategic goals.

Comparison to Industry Standards

• The structure of these equity grants, with multi-year vesting periods, is consistent with common executive compensation practices observed across the biotech and pharmaceutical sectors.
• The use of both restricted stock units (RSUs) and stock options is a typical approach to provide a balanced incentive, offering both retention value (RSUs) and performance-based upside (options).

Stakeholder Impact

• Shareholders: The grants align the Chief People Officer's financial interests with the company's long-term stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Kelley Boucher's continued service will be required for the vesting of the restricted stock units and stock options.
• The company's stock performance will influence the ultimate value of these equity awards.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a company executive, which is a standard practice for aligning management incentives with shareholder interests. It does not contain information that would fundamentally alter the investment thesis for Apellis Pharmaceuticals, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Kelley Boucher, Chief People Officer, SEC Form 4, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, 10b5-1 Plan